ESC 365 - What is the evidence for SGLT2 inhibitors in HF?

Open Access

What is the evidence for SGLT2 inhibitors in HF?

Session: SGLT2 inhibitors in practice (part 4): initiating heart failure treatment in hospital

Topic: Chronic Heart Failure, Other

Speaker: Professor P. Ponikowski (Wroclaw, PL)

Sponsored by Boehringer Ingelheim & Eli Lilly

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Piotr Ponikowski

Wroclaw Medical University, Wroclaw (Poland)

111 presentations

15 followers

4 more presentations in this session

Introduction and recap.

Speaker: Professor J. Butler (Dallas, US)

Implementing in-hospital initiation of an SGLT2 inhibitor in my practice.

Speaker: Doctor M. Costanzo (Naperville, US)

Panel discussion.

Speaker: Professor S. Anker (Berlin, DE)

SGLT2 inhibitors in practice: what are the next steps?

Speaker: Professor S. Anker (Berlin, DE)

Access the full session

SGLT2 inhibitors in practice (part 4): initiating heart failure treatment in hospital

Speakers: Professor P. Ponikowski, Professor J. Butler, Doctor M. Costanzo, Professor S. Anker, Professor S. Anker

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources